The National Heart, Lung, and Blood Institute (NHLBI) awarded Brigham & Women's Hospital Inc. a $167,400 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) with a start date of March 1, 2025 and an end date of February 28, 2030. The purpose of this grant is to investigate how the immune mediator CD70 regulates endothelial and metabolic pathways to potentially serve as a novel therapeutic target for atherosclerotic cardiovascular disease. The proposed research aims to elucidate the mechanisms by which CD70 impacts endothelial nitric oxide synthase activity, endothelial cell metabolism, and vascular inflammation, with the goal of advancing scientific understanding and identifying new treatment approaches. The grant supports a comprehensive career development plan for the principal investigator to establish himself as an independent physician-scientist in the field of vascular biology and immuno-metabolic regulation of endothelial and vascular function.
Generated 3/18/25, 4:32 AM